A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden

Página do item simplificado
dc.creatorBruno Mendes Roatt
dc.creatorJesus Valenzuela
dc.creatorRodrigo Corrêa Oliveira
dc.creatorRodolfo Cordeiro Giunchetti
dc.creatorAlexandre Barbosa Reis
dc.creatorRodrigo Dian de Oliveira Aguiar Soares
dc.creatorLevi Eduardo Soares Reis
dc.creatorJamille Mirelle de Oliveira Cardoso
dc.creatorFernando Augusto Siqueira Mathias
dc.creatorRory Cristiane Fortes de Brito
dc.creatorNelder Figueiredo Gontijo
dc.creatorSidney de Almeida Ferreira
dc.creatorSydnei Magno da Silva
dc.date.accessioned2023-06-15T21:28:25Z
dc.date.accessioned2025-09-09T01:12:23Z
dc.date.available2023-06-15T21:28:25Z
dc.date.issued2017
dc.identifier.doihttps://doi.org/10.3389/fimmu.2017.00217
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/1843/54981
dc.languagepor
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofFrontiers in immunology
dc.rightsAcesso Aberto
dc.subjectVacina
dc.subjectImunoterapia
dc.subject.otherHeterologous vaccine therapy
dc.subject.otherImmunotherapy
dc.subject.otherCanine visceral leishmaniasis
dc.subject.otherL. infantum
dc.subject.otherImmune response
dc.titleA vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden
dc.typeArtigo de periódico
local.citation.epage14
local.citation.issue217
local.citation.spage1
local.citation.volume8
local.description.resumoHerein, we evaluated the treatment strategy employing a therapeutic heterologous vaccine composed of antigens of Leishmania braziliensis associated with MPL adjuvant (LBMPL vaccine) for visceral leishmaniasis (VL) in symptomatic dogs naturally infected by Leishmania infantum. Sixteen dogs received immunotherapy with MPL adjuvant (n = 6) or with a vaccine composed of antigens of L. braziliensis associated with MPL (LBMPL vaccine therapy, n = 10). Dogs were submitted to an immunotherapeutic scheme consisting of 3 series composed of 10 subcutaneous doses with 10-day interval between each series. The animals were evaluated before (T0) and 90 days after treatment (T90) for their biochemical/hematological, immunological, clinical, and parasitological variables. Our major results showed that the vaccine therapy with LBMPL was able to restore and normalize main biochemical (urea, AST, ALP, and bilirubin) and hematological (erythrocytes, hemoglobin, hematocrit, and platelets) parameters. In addition, in an ex vivo analysis using flow cytometry, dogs treated with LBMPL vaccine showed increased CD3+ T lymphocytes and their subpopulations (TCD4+ and TCD8+), reduction of CD21+ B lymphocytes, increased NK cells (CD5−CD16+) and CD14+ monocytes. Under in vitro conditions, the animals developed a strong antigen-specific lymphoproliferation mainly by TCD4+ and TCD8+ cells; increasing in both TCD4+IFN-γ+ and TCD8+IFN-γ+ as well as reduction of TCD4+IL-4+ and TCD8+IL-4+ lymphocytes with an increased production of TNF-α and reduced levels of IL-10. Concerning the clinical signs of canine visceral leishmaniasis, the animals showed an important reduction in the number and intensity of the disease signs; increase body weight as well as reduction of splenomegaly. In addition, the LBMPL immunotherapy also promoted a reduction in parasite burden assessed by real-time PCR. In the bone marrow, we observed seven times less parasites in LBMPL animals compared with MPL group. The skin tissue showed a reduction in parasite burden in LBMPL dogs 127.5 times higher than MPL. As expected, with skin parasite reduction promoted by immunotherapy, we observed a blocking transmission to sand flies in LBMPL dogs with only three positive dogs after xenodiagnosis. The results obtained in this study highlighted the strong potential for the use of this heterologous vaccine therapy as an important strategy for VL treatment.
local.identifier.orcidhttps://orcid.org/0000-0001-5281-3263
local.identifier.orcidhttps://orcid.org/0000-0002-5589-9450
local.identifier.orcidhttps://orcid.org/0000-0001-6419-9459
local.identifier.orcidhttps://orcid.org/0000-0003-4181-7546
local.identifier.orcidhttps://orcid.org/0000-0001-8123-4164
local.identifier.orcidhttps://orcid.org/0000-0002-3390-7990
local.identifier.orcidhttps://orcid.org/0000-0003-0781-9556
local.identifier.orcidhttps://orcid.org/0000-0003-2071-0344
local.identifier.orcidhttps://orcid.org/0000-0002-7591-5331
local.identifier.orcidhttps://orcid.org/0000-0002-1398-3777
local.identifier.orcidhttps://orcid.org/0000-0003-3154-5663
local.publisher.countryBrasil
local.publisher.departmentICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE MORFOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE PARASITOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.frontiersin.org/articles/10.3389/fimmu.2017.00217/full

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.pdf
Tamanho:
1.6 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG